# Jubilant Pharmova Limited (JUBLPHARMA)

> JUBLPHARMA closed at ₹925.60 on 30 Oct 2026, trailing P/E 41.5, market cap ₹14,624 cr, latest results for the quarter ended 30 Jun 2026. Revenue, profit, ROE, debt, own P/E range and sector-peer comparison from the SEBI filing.

Jubilant Pharmova Limited (NSE: JUBLPHARMA) closed at ₹925.60 on 30 Oct 2026, -14.3% over one year, against a 52-week range of ₹786.05 – ₹1,184.80.

In the quarter ended 30 Jun 2026 (consolidated, filed 10 Aug 2026) it reported revenue of ₹2,229 cr and net profit of ₹57 cr, a 2.5% net margin; revenue grew 17.3% and profit fell 44.1% year on year.

On four consecutive filed quarters its trailing P/E is 41.5; since 16 May 2025 its own P/E has ranged from 17.7 to 48.2 (median 23.0), and today's reading is higher than 90% of those 360 trading days.

From the balance sheet dated 31 Mar 2026: return on equity 3.2%, ROCE 4.3%, debt-to-equity 0.45, Piotroski F-score 4 of 9.

Against 65 Healthcare peers on NSE: Net margin higher than 8% of 63 sector peers; PBT margin higher than 8% of 63 sector peers; ROE higher than 11% of 63 sector peers.

## Key figures

| Figure | Value |
|---|---|
| Last close | ₹925.60 (30 Oct 2026) |
| Change 1 month / 6 months / 1 year | -13.0% / -2.1% / -14.3% |
| 52-week low – high | ₹786.05 – ₹1,184.80 |
| Market capitalisation | ₹14,624 cr |
| Trailing P/E | 41.5 |
| Price / book | 2.06 |
| EV / EBITDA | 13.5 |
| Earnings yield | 2.4% |
| TTM EPS | ₹22.28 |
| TTM net profit | ₹352 cr |
| Quarter revenue | ₹2,229 cr |
| Quarter net profit | ₹57 cr |
| Net margin | 2.5% |
| Revenue growth (YoY) | +17.3% |
| Profit growth (YoY) | -44.1% |
| Return on equity | 3.2% |
| ROCE | 4.3% |
| Debt / equity | 0.45 |
| Current ratio | 1.62 |
| Free cash flow | ₹-222 cr |
| Piotroski F-score | 4 / 9 |
| Average daily turnover (50 days) | ₹17.5 cr |

## Questions

### What is the P/E ratio of Jubilant Pharmova Limited?

Jubilant Pharmova Limited's trailing P/E is 41.5, using the close of 30 Oct 2026 and earnings over the four filed quarters to 30 Jun 2026. Since 16 May 2025 its P/E has ranged 17.7–48.2.

### What were Jubilant Pharmova Limited's latest quarterly results?

For the quarter ended 30 Jun 2026, Jubilant Pharmova Limited reported revenue of ₹2,229 cr and net profit of ₹57 cr (consolidated), filed with the exchange on 10 Aug 2026.

### What is Jubilant Pharmova Limited's ROE?

Return on equity is 3.2% based on the balance sheet dated 31 Mar 2026.

### Does Jubilant Pharmova Limited have debt?

Debt-to-equity is 0.45 on the balance sheet dated 31 Mar 2026.

### What is JUBLPHARMA's 52-week high and low?

Over the last 52 weeks to 30 Oct 2026, JUBLPHARMA traded between ₹786.05 and ₹1,184.80.

Sector: [Healthcare](https://trinetra.trade/sectors/healthcare) · Page: https://trinetra.trade/fundamentals/JUBLPHARMA

_TRINETRA is a research and education tool. Nothing on this site is investment advice or a recommendation to buy or sell any security. Markets carry risk; do your own research and consult a SEBI-registered adviser before investing._